Results 11 to 20 of about 78,101 (219)

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects [PDF]

, 2015
The steady-state concentrations of meropenem and the β-lactamase inhibitor RPX7009 in plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations were obtained in 25 healthy, nonsmoking adult subjects.
Jeffrey S. Loutit, Mark H. Gotfried, JS Loutit (7942544), E Wenzler (7942538), MH Gotfried (7942541), MN Dudley (7942553), Michael N. Dudley, Stephanie Durso, Eric Wenzler, S Durso (7942547), David C. Griffith, KA Rodvold (7942556), DC Griffith (7942550), Keith A. Rodvold   +13 more
core   +7 more sources

Successful treatment of multidrug resistant Acinetobacter baumannii meningitis

Journal of Infection in Developing Countries, 2007
Background: Acinetobacter baumannii is a major cause of nosocomial infections in many hospitals and appears to have a propensity for developing multiple antimicrobial resistance rapidly.Cases: We report two cases with post-surgical meningitis due to ...
Acinetobacter baumannii, Post-surgical meningitis, High dose meropenem
doaj   +1 more source

Empirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial. [PDF]

Acta Anaesthesiol Scand
ABSTRACT Background Meropenem and piperacillin/tazobactam are commonly used empirical antibiotics in critically ill adults with sepsis, but whether one is superior to the other is uncertain. Methods The Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) trial is an ongoing investigator‐initiated, randomised ...
Meier NF, Møller MH, Kjær MN, Sjövall F, Munch MW, Kaas-Hansen BS, Thorsen-Meyer HC, Rasmussen BS, Helleberg M, Hertz FB, Lange T, Jensen AKG, Andersen LW, Andersen JS, Michelsen J, Andersen LPK, Bestle MH, Brøchner AC, Itenov TS, Christensen S, Plovsing RTR, Koch KU, Møller A, Schjørring OL, Cranø NB, Vamdrup-Andersen K, Placido D, Meyhoff TS, Anthon CT, Tøgern A, Grigonyte-Daraskeviciene M, Engbakken Z, Kamstrup AW, Uhre KR, Barakji JA, Larsen RF, Perner A, Granholm A.   +37 more
europepmc   +2 more sources

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

, 2022
The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin.
Evangelos J. Giamarellos-Bourboulis (8774799), Maria Mouktaroudi (368377), Antigone Kotsaki (511851)   +2 more
core   +1 more source

Microbacterium spp. peritonitis in patients undergoing peritoneal dialysis: a single-center experience and literature review

Frontiers in Medicine, 2023
IntroductionPeritoneal dialysis-related peritonitis (PDRP) caused by Microbacterium spp. is very rare, with only 9 cases reported to date. In this study, we report the treatment experiences of 7 patients at our peritoneal dialysis center.MethodsWe ...
Xiao Yu, Xiao Yu, Zhao Li, Xinbo Yang, Xiaopei Wang, Di Nan, Wanhong Lu, Jing Lv, Ying Ma   +8 more
doaj   +1 more source

The Case for Intermittent Carbapenem Dosing in Stable Haemodialysis Patients

Antibiotics, 2020
Purpose: Antimicrobial resistant infections are common in patients on haemodialysis, often needing long courses of carbapenems. This results in a longer hospital stay and risk of iatrogenic complications.
Vanda Ho, Felecia Tay, Jia En Wu, Lionel Lum, Paul Tambyah   +4 more
doaj   +1 more source

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance

Antibiotics, 2023
Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives.
Anna Duda-Madej, Szymon Viscardi, Ewa Topola   +2 more
doaj   +1 more source

Correlation between Acinetobacter baumannii Resistance and Hospital Use of Meropenem, Cefepime, and Ciprofloxacin: Time Series Analysis and Dynamic Regression Models

Pathogens, 2021
Acinetobacter baumannii is one of the most difficult-to-treat pathogens worldwide, due to developed resistance. The aim of this study was to evaluate the use of widely prescribed antimicrobials and the respective resistance rates of A.
Rania Kousovista, Christos Athanasiou, Konstantinos Liaskonis, Olga Ivopoulou, George Ismailos, Vangelis Karalis   +5 more
doaj   +1 more source

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients

Antibiotics, 2023
Various studies have reported insufficient beta-lactam concentrations in critically ill patients. The optimal dosing strategy for beta-lactams in critically ill patients, particularly in septic patients, is an ongoing matter of discussion.
Ute Chiriac, Daniel Richter, Otto R. Frey, Anka C. Röhr, Sophia Helbig, Stefan Hagel, Uwe Liebchen, Markus A. Weigand, Alexander Brinkmann   +8 more
doaj   +1 more source

Meropenem extraction by ex vivo extracorporeal life support circuits [PDF]

, 2023
Background: Meropenem is a broad-spectrum carbapenem-type antibiotic commonly used to treat critically ill patients infected with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. As many of these patients require extracorporeal membrane
Whelan Aviva, Green Danielle J., McKnite Autumn, Watt Kevin M., McDaniel Charles Griffin, Hunt J. Porter, Honeycutt Christopher Cole   +6 more
core   +2 more sources